A Novel Molecular Mechanism of Primary Resistance to FLT 3-Kinase Inhibitors in Acute Myeloid Leukemia

1 3 Medical Department, Johannes Gutenberg-University, Mainz, Germany 2 Institute of Molecular Cell Biology, University of Jena, Jena, Germany 3 Experimental Clinical Chemistry, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden 4 current address: Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen, Germany 5 both authors contributed equally 6 current address: Department of Hematology/Oncology, Medical Center, Otto-vonGuericke University Magdeburg, Magdeburg, Germany

[1]  T. Haferlach,et al.  Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. , 2009, Blood.

[2]  M. Caligiuri,et al.  Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity , 2007, Clinical Cancer Research.

[3]  N. Barbarroja,et al.  Inhibition of Flt3‐activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small‐molecule inhibitors , 2007, Hematological oncology.

[4]  Kyu-Tae Kim,et al.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. , 2006, Blood.

[5]  P. Roller,et al.  Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics. , 2006, Biochemical and biophysical research communications.

[6]  D. Gilliland,et al.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. , 2006, Blood.

[7]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[8]  Megan L. Peach,et al.  Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives. , 2006, Journal of medicinal chemistry.

[9]  Richard Clark,et al.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. , 2004, Blood.

[10]  R. Stone,et al.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. , 2006, Blood.

[11]  S. Jayaraman Flow cytometric determination of mitochondrial membrane potential changes during apoptosis of T lymphocytic and pancreatic beta cell lines: comparison of tetramethylrhodamineethylester (TMRE), chloromethyl-X-rosamine (H2-CMX-Ros) and MitoTracker Red 580 (MTR580). , 2005, Journal of immunological methods.

[12]  F. Bussolino,et al.  Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. , 2005, Blood.

[13]  G. Gores,et al.  Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. , 2005, Gastroenterology.

[14]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[15]  E. Estey,et al.  Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). , 2005, Blood.

[16]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[17]  Doriano Fabbro,et al.  Prediction of Resistance to Small Molecule FLT3 Inhibitors , 2004, Cancer Research.

[18]  H. Pehamberger,et al.  Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma , 2004, Clinical Cancer Research.

[19]  A. Marx,et al.  Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.

[20]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[21]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[22]  G. Mcmahon,et al.  SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. , 2002, Blood.

[23]  Martin Dugas,et al.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. , 2002 .

[24]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[25]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[26]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[27]  M. Yaffe Phosphotyrosine-binding domains in signal transduction , 2002, Nature Reviews Molecular Cell Biology.

[28]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[29]  H. Broxmeyer,et al.  Flt3 signaling involves tyrosyl‐phosphorylation of SHP‐2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells , 1999, Journal of leukocyte biology.

[30]  D. Allen,et al.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM , 1998, Nature.

[31]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[32]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[33]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[34]  J. Darnell,et al.  Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation , 1995, Cell.

[35]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.